Gomari et al. fused HER2 targeting DARPins (designed ankyrin repeat proteins) to Lamp2b to target HER2-positive breast cancer, which resulted in a four-fold increased delivery of engineered exosomes to HER2 positive BT-474 breast cancer cells in vitro [97]. Here, ERBB2 is linked to breast carcinoma.